Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

SLB 2025- Inflammation: A Goldilocks Story

December 10, 2024Society for Leukocyte Biology

Spotlight on Veterinary Immunology: Highlights from ALACI 2024

December 10, 2024Veterinary Immunology Committee (VIC)

Announcing the Recipients of the 2024 Travel4Expertise Grant!

December 2, 2024Gender Equity Committee (GEC)

Clarification on Unaffiliated Events

October 29, 2024

New Opportunities to Partner with Daiichi Sankyo and BASF

October 21, 2024

IUIS Junior Community’s New Board Is Here!

October 21, 2024Early Career Committee (ECC)

IUIS 2025: Empower the Next Generation of Scientists!

October 10, 2024

Call for Applications to the IUIS T-cell and Immunoglobin Nomenclature Sub-Committee & Application Form

October 8, 2024Canadian Society for Immunology, Nomenclature Committee (NOM)

Three Scholarships to Attend 20th Spring School on Immunology in Ettal, Bavaria, Germany

October 1, 2024Deutsche Gesellschaft für Immunologie